Mathieu Puyade1, Emilie Cayssials1, Fabrice Pierre2, Olivier Pourrat3. 1. CHU de Poitiers, Service Onco-Hématologie et Thérapie Cellulaire, Poitiers, France. 2. CHU de Poitiers, Service de Gynécologie Obstétrique, Poitiers, France. 3. CHU de Poitiers, Obstetric Medicine Clinic, Service de Réanimation Médicale et de Médecine Interne, Poitiers, France.
Abstract
BACKGROUND: The most frequent myeloproliferative neoplasms are essential thrombocythemia and chronic myelogenous leukemia, which usually manifests with thrombocytosis. Only essential thrombocythemia is associated with morbidity during pregnancy (recurrent miscarriages, intrauterine fetal death, small for gestational age and preeclampsia). The aim of this paper is to describe outcomes of pregnancy in women with myeloproliferative neoplasms seen at a single academic institution. METHODS: Data were collected retrospectively from 2002 to 2015. Descriptive analyses were performed. RESULTS: Eighteen pregnancies in 13 patients and 17 births were identified. One patient had recurrent miscarriages. There were two intrauterine fetal deaths, three small for gestational age linked to vascular placenta pathology and one preeclampsia. All of these mothers harbored JAK2V617F mutation. Two out of three patients with small for gestational age developed a venous thrombosis in the two years following delivery. CONCLUSION: Thrombocytosis associated with myeloproliferative neoplasms should be considered as a risk factor for maternal and fetal complications.
BACKGROUND: The most frequent myeloproliferative neoplasms are essential thrombocythemia and chronic myelogenous leukemia, which usually manifests with thrombocytosis. Only essential thrombocythemia is associated with morbidity during pregnancy (recurrent miscarriages, intrauterine fetal death, small for gestational age and preeclampsia). The aim of this paper is to describe outcomes of pregnancy in women with myeloproliferative neoplasms seen at a single academic institution. METHODS: Data were collected retrospectively from 2002 to 2015. Descriptive analyses were performed. RESULTS: Eighteen pregnancies in 13 patients and 17 births were identified. One patient had recurrent miscarriages. There were two intrauterine fetal deaths, three small for gestational age linked to vascular placenta pathology and one preeclampsia. All of these mothers harbored JAK2V617F mutation. Two out of three patients with small for gestational age developed a venous thrombosis in the two years following delivery. CONCLUSION: Thrombocytosis associated with myeloproliferative neoplasms should be considered as a risk factor for maternal and fetal complications.